- Coordinator
- Spacepharma R&d Israel Ltd, Israel
- Runs
- 1 August 2024 to 30 September 2026
- Status
- Running
- EU funding
- €2.2m
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Innovation Council
- Grant agreement
- 101189238
What the project is doing
In the project's own words, from its summary on CORDIS.
Over 2,000 R&D experiments have been done in Space until now. Space near-zero gravity yields biochemical crystals orders of magnitude more defined, pure, uniform, and precise than in terrestial environments. The low-gravity accelerates the development and preclinical testing of complex molecules –e.g. proteins- and unleashes the potential of innovative high-value mAbs therapies, saving patient’s lives and improving their QoL.To make it real, after 11 space missions, SPACEPHARMA is committed to bringing the first mAbs factory to Space.
MOTI, the main SPACTORY building block, brings accessible, scalable, and affordable microgravity manufacturing controlled from Earth and able to fly in any satellite compatible with any launcher. For our customers, the pharma industry, it means shorter time to Space, faster market access and affordable drug development. For SPACEPHARMA, it is a paradigm shift from drug R&D to manufacturing. For EU, it means leading the spatial race in drug development.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| Spacepharma R&d Israel Ltd | Herzliya Pituach | Israel | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI